No Data
Minsheng Securities: Triple resonance moving upwards, focusing on pharmaceutical innovation and Consumer in 2025.
Looking ahead to 2025, there is a bullish outlook on the upward resonance of policy, fundamentals, and market sentiment, comprehensively optimistic about the pharmaceutical sector, with a focus on high-quality assets in pharmaceutical innovation and consumer sectors.
How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.
On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.
Open Source Securities: DLL3 is a star target with high expression in SCLC, and various domestic new drugs can be expected in the future.
DLL3 is highly expressed in 80% of SCLC patients, providing a better solution for targeted therapy. Currently, only one product targeting this point has been approved for market, resulting in a favorable competitive landscape.
INNOVENT BIO has risen over 4% after reaching a clinical research and drug supply cooperation agreement with Fulong Bio.
INNOVENT BIO (01801) stock price continues to rise, up by 4.35%, currently reported at 37.15 HKD, with a trading volume of 83.8732 million HKD. INNOVENT BIO announced a clinical research and drug supply cooperation agreement with Fubion Biotech to jointly explore the potential of the combination treatment of Dabushu (Sintilimab injection, a PD-1 inhibitor) and FL115 (an IL-15 superagonist) in patients with advanced solid tumors.
INNOVENT BIO (01801): Gary Zieziula has been appointed as a member of the Compensation Committee.
INNOVENT BIO (01801) released an announcement that Chen Kaixian has submitted his resignation as an independent non-executive director to focus on Other career developments...
Innovent Biologics' Lung Cancer Drug Hets NDA Approval From China's NMPA
No Data
